Clinical pharmacology of 1-beta-d-arabinofuranosyl cytosine.
D000284:Administration, Oral; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001089:Arabinose / Q000097:blood / Q000652:urine; D003561:Cytarabine / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism / Q000494:pharmacology* / Q000652:urine; D004912:Erythrocytes / Q000032:analysis; D006207:Half-Life; D006801:Humans; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D007278:Injections, Spinal; D007939:Leukemia L1210 / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D051379:Mice; D009368:Neoplasm Transplantation; D009705:Nucleosides / Q000097:blood / Q000652:urine; D013997:Time Factors; D014316:Tritium; D014498:Uracil / Q000097:blood / Q000652:urine
D000970:Antineoplastic Agents; D009705:Nucleosides; D003561:Cytarabine; D014316:Tritium; D014498:Uracil; D001089:Arabinose